Kancera develops drugs that counteract damage from acute and chronic inflammation. Fraktalkine blocker KAND567 is developed primarily to effectively counteract hyperinflammation in various medical conditions and thus protect vital organs, e.g. in connection with heart attacks and severe viral infections. In the second quarter of 2020,
The share is traded on NASDAQ First North Premier. FNCA Sweden AB is the company’s Certified Adviser. FNCA can be reached on firstname.lastname@example.org and on 08-528 00 399. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.